Department of Biochemistry and Molecular
Biology, Mount Sinai School of Medicine, New York, New York
10029,1 and Department of Protein
Science, Pharmacia and Upjohn, Inc., Kalamazoo, Michigan
490012
Received 13 June 2000/Returned for modification 18 July
2000/Accepted 2 April 2001
Receptor tyrosine kinases may use intrasteric inhibition to
suppress autophosphorylation prior to growth factor stimulation. To
test this hypothesis we made an Asp1161Ala mutant in the activation loop that relieved intrasteric inhibition of the unphosphorylated insulin receptor (IR) and its recombinant cytoplasmic kinase domain (IRKD) without affecting the activated state. Solution studies with the
unphosphorylated mutant IRKD demonstrated conformational changes and
greater catalytic efficiency from a 10-fold increase in
kcat and a 15-fold-lower
Km ATP although
Km peptide was unchanged.
Kinetic parameters of the autophosphorylated mutant and wild-type
kinase domains were virtually identical. The Asp1161Ala mutation
increased the rate of in vitro autophosphorylation of the IRKD or IR at
low ATP concentrations and in the absence of insulin. However,
saturation with ATP (for the IRKD) or the presence of insulin (for the
IR) yielded equivalent rates of autophosphorylation for mutant versus
wild-type kinases. Despite a biochemically more active kinase domain,
the mutant IR expressed in C2C12 myoblasts was not constitutively
autophosphorylated. However, it displayed a 2.5-fold-lower 50%
effective concentration for insulin stimulation of autophosphorylation
and was dephosphorylated more slowly following withdrawal of insulin
than wild-type IR. In tests of the regulation of the unphosphorylated
basal state, these results demonstrate that neither intrasteric
inhibition against ATP binding nor suppression of kinase activity is
required to prevent premature autophosphorylation of the IR. Finally,
the lower rate of dephosphorylation suggests invariant residues of the
activation loop such as Asp1161 may function at multiple junctures in
cellular regulation of receptor tyrosine kinases.
 |
INTRODUCTION |
Signal transduction through receptor
tyrosine kinases (RTKs) is essential throughout the life of an
organism. The tight control of RTK signaling required for normal
cellular function is dependent on growth factor stimulation of
autophosphorylation (50). Autophosphorylation is a unique
regulatory motif among protein kinase signaling cascades because no
other enzyme precedes or participates in autophosphorylation. Therefore
the unphosphorylated RTK must have sufficient catalytic activity to
perform the first phosphoryl transfer reaction while (i) avoiding
autophosphorylation prior to growth factor binding and (ii) avoiding
target phosphorylation prior to autophosphorylation. The first
restriction is met by hormone-induced dimerization of monomeric RTKs
(50), where the homodimer itself provides the enzyme-substrate pair. The second restriction is met by target or
mediator recruitment sites which appear on the RTK as a consequence of
autophosphorylation (44, 51). The logic of induced
dimerization seems to fail when applied to the insulin receptor (IR).
The IR is a heterotetramer with an
2
2-subunit structure.
The extracellular
-subunits are covalently linked to each other and
to the membrane-spanning
-subunits by disulfide bonds
(36). Nevertheless this dimerized RTK retains an
unphosphorylated basal state and does not autophosphorylate or signal
until insulin binds.
The IR's recombinant cytoplasmic kinase domain (IRKD) (residues
954 to 1382, numbered according to Ebina et al. [14])
has been used as a biochemically and biophysically tractable model for
kinase activity of the full-length IR. It has kinetic features similar
to the basal state of the IR (32, 34), and it can be
activated by autophosphorylation (11, 53, 55) so that its
structure should reveal aspects of the kinase important for the
receptor's function and regulation (24, 26). The crystal structure of the catalytic core (residues 978 to 1283)
(26) identified the activation loop (residues D1150 to
P1172) as an intrasteric inhibitor which blocked entry of both
substrates to the active site. Neither ATP nor peptide can bind in the
active site if the activation loop remains in this "gate-closed"
conformation, rendering the kinase latent as an enzyme. Also,
Y1162
among the first tyrosines to be autophosphorylated (17,
27, 46, 48, 49, 55, 58)
is sterically inaccessible and
therefore cannot be phosphorylated by a trans
autophosphorylation reaction (26). The gate-closed form of
the kinase is also latent as a substrate. This dual latency is capable
of maintaining an unphosphorylated basal state for the full-length IR
because it is not compatible with autophosphorylation.
There is compelling biophysical evidence that a latent form of the
kinase accounts for >90% of the IRKD in solution when substrates are
absent (3, 18). However, previous studies with the native IR demonstrated that occupancy of the binding site by ATP or
nonhydrolyzable analogs promoted trans interactions
(57) and conformational changes in the receptor
(39) and in particular enhanced the autophosphorylation
that is responsible for kinase activation (41).
Furthermore, kinetic evidence showed that ATP binding predisposes the
unphosphorylated receptor for trans autophosphorylation (32). Given the apparent affinity of the kinase domain for
MgATP of ~1 mM (1, 7, 18) and the intracellular ATP
concentration of ~1 mM (possibly as high as 8 mM
[37]), a significant fraction of the receptor's kinase
domains should have nucleotide bound under physiological conditions and
therefore should be nonlatent as an enzyme and nonlatent as a substrate
(18). This raises the issue of whether latency is required
to maintain the basal state and, conversely, whether the IR with
nonlatent kinase domains can be kept from autophosphorylation and
signaling. With a single point mutant, we have established a
predominantly gate-open state that is relieved of latency. It displays
a high turnover number and improved ATP binding, so that it will be
saturated at physiological concentrations of ATP and capable of
more-rapid autophosphorylation than the native receptor. We used this
mutant to test intrasteric inhibition against ATP binding as a
potential regulator of the IR's basal state.
 |
MATERIALS AND METHODS |
Materials.
Dithiothreitol (DTT; Sigma Ultra), the disodium
salt of ATP (from equine muscle, catalog no. A-5394), ADP, bovine serum
albumin (BSA; radioimmunoassay grade), and wheat germ agglutinin
(WGA)-agarose were purchased from Sigma; hydrogenated Triton X-100
(protein grade) was from Calbiochem; EDTA was from Fluka; Tris acetate (TrisAc), Tris base, Tris HCl, Triton X-100, and electrophoresis reagents were from Boehringer Mannheim; magnesium acetate
(MgAc2; enzyme grade) was from Fisher. Insect and
mammalian cell culture media and fetal bovine serum were from Gibco/BRL
and Cellgro. The synthetic peptide used for steady-state kinetics has
the amino acid sequence REETGSEYMNMDLG (IRS939). It
was prepared by 9-fluoroenylmethoxy carbonyl chemistry and purified
(8). Adenine nucleotides and the synthetic peptide were
dissolved in 50 mM TrisAc, pH 7.0, and the pH was readjusted to 7.0. These stocks were kept at
20°C for frequent use or at
80°C for
storage. The concentrations of adenine nucleotides and synthetic
peptides were determined spectrophotometrically: for ATP and ADP,
= 15,300 cm
1
M
1 at 259 nm; for IRS939,
= 1,300 cm
1 M
1 at 278 nm.
Mutagenesis, IRKD protein expression, and purification.
Baculovirus encoding the IRKD (amino acid residues 953 to 1355 of the
IR) was a generous gift of the late Ora Rosen (53). The
D1161A-IRKD mutant was subcloned in this laboratory using a human IR
cDNA originally provided by Jonathan Whittaker (56). The
mutation was generated by overlap-extension PCR (22) using pXCKD as the template (6). The mutagenic oligonucleotide
primers were 5'-TGAAACGGCGTACTACCGG-3'
and 5'-CCGGTAGTACGCCGTTTCA-3' with the nucleotide changes shown in boldface and the altered coding triplet underlined. The 570-bp PCR product was digested with
BstXI and StuI, and the resulting 421-bp fragment
was ligated into pXCKD, generating pX-D1161A-IRKD. The mutation was
verified by DNA sequencing. A 1,670-bp EcoRI-PstI
fragment including the coding region of D1161A-IRKD along with 5' and
3' untranslated regions was inserted into the
EcoRI-PstI sites in the baculovirus expression
vector pVL1393 (PharMingen). A 34-kDa form of D1161A-IRKD was made by
swapping a 420-bp BstXI/StuI fragment into
pX-
IRKD (18), which lacks amino-terminal and
carboxy-terminal autophosphorylation sites, for use in determining
basal state steady-state kinetic parameters (see reference
1). The virus for D1161A-IRKD was generated by
cotransfection of Sf9 cells using the Baculogold Kit (PharMingen).
Virus was amplified by suspension culture of Sf9 cells grown in spinner
flasks, and the titers of the virus were determined with Hi5 cells
(Invitrogen) by standard procedures (40). Viral infections
to produce protein in Hi5 cells were done for 3 to 4 h at a
multiplicity of infection of 10. The infection medium was then replaced
with fresh medium. Cells were harvested at 53 h from the start of
infection. Cells were resuspended in homogenization buffer (250 mM
sucrose, 50 mM Tris base, 20 mM NaCl [pH 7.5]) and stored at
80°C,
at least overnight. IRKD purification was done by ion exchange and size
exclusion chromatography with a Pharmacia FPLC chromatograph as
described in Bishop et al. (3). The purified protein was
quantified spectrophotometrically (at 278 nm,
= 40,200 cm
1 M
1) and stored at
20°C in 35% (vol/vol) glycerol, prepared as 38% (wt/wt).
Subcloning D1161A-IR and transient expression in C2C12
myoblasts.
The D1161A-IR was generated by ligating the 1.6-kb
BglI-XbaI fragment from the pX-D1161A-IRKD
plasmid with the 7-kb BamHI/XbaI and 1.1-kb
BamHI/BglI fragments from pEF-IR (cDNA of the
human IR in a vector with the EF-1 promoter to drive expression;
Invitrogen). Transfections in subconfluent monolayers of C2C12 cells in
10-cm dishes were done with FuGene (Boehringer Mannheim) and 10 µg of endotoxin-free plasmid [Qiagen Maxiprep kit; pBluescript SK(+) was
used for the mock transfection]. Monolayers were incubated overnight
and then passed by trypsinization into replicate culture dishes and
regrown overnight.
Limited tryptic cleavage of IRKD.
Limited proteolysis of the
wild-type IRKD (WT-IRKD) and D1161A-IRKD was done according to
Frankel et al. (18).The IRKD was digested at 5 µM in 50 mM TrisAc, 20 mM MgAc2, 1 mM DTT, and 2 mM
CaCl2 (pH 7.0), with or without 10 mM ADP.
Trypsin was added to a ratio of trypsin to IRKD of 1:20 by mass. The
reaction proceeded for 16 min and was then quenched with a one-half
volume of threefold-concentrated Laemmli sample buffer
(35). The digestion products were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and the
fragments were visualized by silver staining, as described (7). The developed slab gels were scanned with an Arcus II scanner (Agfa) with Fotolook and Photoshop software (Adobe).
Fluorescence spectroscopy and iodide quenching.
Steady-state
fluorescence emission spectra were obtained with an SLM 4800 spectrofluorometer operating in the single-photon counting mode. Magic
angle polarization conditions were adopted with the excitation
polarizer set at 55° and the emission polarizer set at 0° to
minimize polarization-dependent intensity artifacts and to minimize the
Wood's anomaly of the emission grating. For intrinsic tryptophan
fluorescence spectra, an excitation wavelength of 300 nm was used with
excitation and emission slits both set at 8-nm band-pass. Measurements
were made at 21°C. Emission spectra were collected over a range of
310 to 420 nm in 1-nm increments. The final spectra were determined
from the average of three spectral scans. Time-resolved fluorescence
measurements by the time-correlated single-photon-counting method were
done with a Coherent laser, according to Hasselbacher et al.
(20).
Iodide quenching was done as described previously (3). The
IRKD was used at 0.6 µM, and quenching was done at 0.0 to 0.6 M KI in
50 mM TrisAc, 20 mM MgAc2, and 0.1 mM sodium
thiosulfate, at pH 7.0. The potassium salt concentration was kept
constant at 0.6 M by the addition of KCl as needed. Integrated emission intensities were determined from the emission spectra, between 310 and
420 nm, taken as described above. Spectra without IRKD were subtracted
for the blank correction, and separate spectra were taken at every
iodide concentration, at 0 or 10 mM ADP. The integrated emission
intensity, F, was plotted against iodide (quencher) concentration Q, according to the Stern-Volmer equation
where F0 is the integrated
fluorescence intensity in the absence of quencher (the average of
triplicate determinations), and Ksv is
the Stern-Volmer quenching constant. The value of
Ksv was determined from modified
Stern-Volmer plots (38) when the initial Stern-Volmer plot
was nonlinear, using a plot of F0
/
F versus 1/Q according to the equation
where fa is the fraction of
intrinsic fluorophores that were subject to quenching and
F = F0
F.
Endoproteinase Lys-C digestion and peptide mapping.
Proteolysis was done for 24 h, with 100 µg of IRKD and 2 µg of
endoproteinase Lys-C in 0.1 ml of 50 mM ammonium bicarbonate with a
second addition of protease at 16 to 18 h. The digests were
lyophilized in a Savant Speed-Vac. Each sample was dissolved in 200 µl of high-performance liquid chromatography (HPLC) buffer A
(0.12% trifluoroacetic acid, 1% methanol, 2% acetonitrile, in water
[vol/vol]), and 10 µl of a 4 mM solution of TCEP (Molecular Probes) was added to reduce disulfide bonds that had formed during digestion in ammonium bicarbonate. The peptides were resolved by
reverse-phase HPLC with a Hewlett-Packard model 1090 liquid chromatograph with a Linear Instruments model 206PHD UV/Vis
spectrometer as the detector. The column was an ODS Hypersil (150 by 2 mm) developed at a flow rate of 0.25 ml/min with a gradient from 2% HPLC buffer A (above) to 50% HPLC buffer B (0.1% trifluoroacetic acid, 1% methanol, 2% water, in acetonitrile [vol/vol]). The
gradient (with buffer B) was 2 to 19 to 40 to 50% at 0, 16, 140, and
150 min, respectively. Peptides were detected at 230, 278, and 295 nm;
the profiles at 230 nm are shown (see Fig. 3). Peptides were recovered and identified by amino acid sequence analysis.
Steady-state kinetics.
Peptide phosphorylation was measured
with IRS939 and the HPLC-based assay described previously
(8). Kinetic studies with WT-IRKD are reported elsewhere
(1). The activated D1161A-IRKD was obtained by
autophosphorylation for 10 min with 2 µM kinase, 1 mM ATP, 20 mM
MgAc2, 50 mM TrisAc, 5 mM DTT, and 0.05%
hydrogenated Triton X-100 (vol/vol) (pH 7.0) at room temperature. The
reaction was quenched with a one-ninth volume of 0.45 M EDTA and kept
on ice. Assays of activity were initiated within 2 h. Under these conditions, D1161A-IRKD reaches maximal phosphorylation and maximal activity. Peptide phosphorylation assays with D1161A-IRKD were done
with 2 nM phospho-D1161A-IRKD or 20 nM unphosphorylated D1161A-IRKD (34-kDa form) in 50 mM TrisAc (pH 7.0), 1 mM DTT, 0.05% (vol/vol) hydrogenated Triton X-100, 20 mM MgAc2 with 0.4 to 4.0 mM variable IRS939 (peptide substrate), and 0.01 to 1.0 mM
variable ATP. The 34-kDa form lacks the amino-terminal juxtamembrane
region and therefore does not undergo partial activation during
substrate phosphorylation reactions (6, 7). Rates of
substrate phosphorylation were linear with time and kinase
concentrations (0.5 to 5 nM activated kinase and 2 to 40 nM
unphosphorylated kinase), indicating no changes in the underlying
kinetic parameters occurred during the measurements. Steady-state
kinetic parameters were obtained by fitting the initial velocity
vi versus the substrate concentrations of
ATP and IRS939 according to the equation
|
|
|
|
where Km MgATP and
Km IRS939 are the Michaelis constants
for nucleotide ATP and peptide IRS939 substrate, respectively, and
kcat is the catalytic rate
constant. Global data fitting was done by nonlinear regression
with SigmaPlot (Jandel Scientific).
Autophosphorylation of WT-IRKD and D1161A-IRKD.
Autophosphorylation was done with 2 µM WT-IRKD or D1161A-IRKD, 50 mM
TrisAc, 20 mM MgAc2, 2 mM DTT, 0.05% (vol/vol)
hydrogenated Triton X-100 (pH 7.0), and either 10 mM or 0.5 mM ATP (for
times, see Fig. 4). The reactions were stopped by the addition
of 1.2 volumes of 75 mM TrisAc, 40 mM EDTA, 20 mM DTT (pH 6.65), and 0.01% bromphenol blue. The products were separated by nondenaturing PAGE, and proteins were detected by silver staining, as described previously (7). The developed slab gels were scanned with
an Arcus II scanner (Agfa) with Fotolook and Photoshop software (Adobe).
Autophosphorylation of WT-IR and D1161A-IR in vitro.
Autophosphorylation was done with D1161A-IR and WT-IR isolated from
monolayers expressing D1161A-IR or WT-IR; two 15-cm culture dishes of
confluent cells were used for each form of the IR and for the
mock-transfected control. The basal state was established by 3 h
of serum deprivation in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 0.2% radioimmunoassay grade BSA, 25 mM HEPES (pH
7.6), and 2 mM L-glutamine (supplemented DMEM).
Monolayers were then washed twice in ice-cold STV buffer (50 mM NaCl,
50 mM Tris, 1 mM Na3VO4
[pH 10.5]) and harvested in STV. All subsequent steps leading up to
the in vitro reaction were done at 4°C. Cells were disrupted by
homogenization, and the membrane fraction was obtained by
ultracentrifugation for 60 min at 250,000 × g.
Membrane proteins were extracted from the pellets by homogenization in STV (pH 7.4) containing 1.2% (wt/vol) Triton X-100, and insoluble material was cleared by ultracentrifugation for 60 min at 250,000 × g. A fraction enriched for the IR was obtained by
adsorption to WGA-agarose and elution in 0.3 M
N-acetylglucosamine in STV (pH 7.4) containing 0.12%
(wt/vol) Triton X-100. The relative quantities of WT-IR and D1161A-IR
were assessed by Western blot analysis of the WGA-agarose eluates with
anti-IRKD antibodies which detected the
-subunit of the full-length
IR; the rabbit polyclonal antibody raised against WT-IRKD recognizes
the mutant and WT proteins equally well, determined from Western blots
of D1161A-IRKD and WT-IRKD where the quantities of purified protein loaded in each lane of the gel were known with precision (data not
shown). Based on these determinations, the amounts of D1161A-IR and
WT-IR loaded per well were the same for all autophosphorylation reactions' time points. The autophosphorylation reactions were carried
out with 50 mM TrisAc, 0.12% (wt/vol) Triton X-100, 0.01 mg of BSA/ml,
20 mM MgAc2 (pH 7.4), and 0.1, 0.5, or 10 mM ATP for 0.5 to 30 min in the absence or presence of 200 nM insulin; reactions were initiated by the addition of ATP and were quenched by
the addition of concentrated Laemmli sample buffer for SDS-PAGE. The
zero time point was quenched before the addition of ATP.
Autophosphorylation was determined by Western blotting with mouse
monoclonal antiphosphotyrosine antibodies and enhanced
chemiluminescence with Kodak XAR X-ray film as described
(54). Western blots were arranged so that a single film
was used for WT-IR and D1161A-IR at each ATP concentration. A separate
gel and blot were used to compare the extent of phosphorylation at 0.1, 0.5, and 10 mM ATP concentrations with samples containing identical
amounts of IR from 30-min reactions of WT-IR and D1161A-IR. Films were
scanned as grayscale images with an Arcus II scanner (Agfa) with
Fotolook and Photoshop software (Adobe). The grayscale images were
analyzed using the Image Quant program (Molecular Dynamics, Sunnyvale,
Calif.). The densities were normalized for the maximum
autophosphorylation of each kinase in the presence of insulin at each
MgATP concentration. A second normalization was done comparing
densities from the Western blots of the 30-min time points. Data are
the averages of triplicate determinations (three separate reactions and
Western blots for each IR at each ATP concentration).
Insulin stimulation in C2C12 myoblasts expressing WT-IR or
D1161A-IR.
Confluent monolayers of C2C12 cells, transiently
expressing D1161A-IR or WT-IR, were prepared as described above with
35-mm culture dishes. The basal state was established by 3 h of
serum deprivation in supplemented DMEM. Cells were stimulated at 37°C in supplemented DMEM with bovine insulin for 8 min (for concentrations used, see Fig. 6 through 8). Monolayers were then washed in
ice-cold phosphate-buffered saline (PBS) and harvested in 0.5 ml of
ice-cold RIPA buffer (200 mM NaCl, 1.2% [wt/vol] Triton X-100, 1%
[wt/vol] deoxycholate, 50 mM Tris [pH 7.0], 1 mM
phenylmethylsulfonyl fluoride, 1 mM
Na3VO4) as described
previously (9). Immunoprecipitation from lysates with
rabbit polyclonal anti-IRKD antibodies or anti-IR substrate 1 (anti-IRS-1) antibodies was performed by incubating 2 µl of antiserum
with 100 µl of cell lysate for 1 h. Immune complexes were bound
to protein A-agarose by incubation at 4°C for 1 h, washed three
times in ice-cold RIPA buffer, resuspended in an equal volume of 2×
Laemmli sample buffer, and incubated at 95°C for 5 min. Western blots
with enhanced chemiluminescence were done from lysates or
immunoprecipitates with mouse monoclonal antiphosphotyrosine antibodies
as described (54).
Time courses of IR phosphorylation and dephosphorylation at 37°C were
obtained using the protocol described in Kohanski et al.
(33) but monitored by antiphosphotyrosine Western blot
analysis. Briefly, confluent monolayers of C2C12 cells, transiently
expressing the D1161A-IR or WT-IR, were prepared in 35-mm culture
dishes and serum deprived as described above. Monolayers were
stimulated with 200 nM insulin in supplemented DMEM (for times used,
see Fig. 8), washed three times in ice-cold PBS, and lysed in
0.5 ml of ice-cold RIPA buffer. Insulin was removed from cells
previously stimulated with 200 nM insulin for 10 min by being washed
rapidly five times with 2 ml of supplemented DMEM. Each
monolayer was covered with 2 ml of supplemented DMEM without insulin
for fixed times (see Fig. 8). Cells were then washed three times
in ice-cold PBS and lysed in 0.5 ml of ice-cold RIPA buffer. Western
blotting from these lysates with mouse monoclonal antiphosphotyrosine
antibodies was performed as described (54).
 |
RESULTS |
Characterization of conformational changes induced by
mutagenesis.
The WT-IRKD and D1161A-IRKD mutant were each purified
as intact 46-kDa proteins (Fig. 1, lanes
1 and 2). Using limited proteolysis as a sensitive indicator of
activation loop conformation (18), we observed
considerable activation loop cleavage in D1161A-IRKD in the absence of
ADP compared to the WT-IRKD control (Fig. 1, lane 5 versus lane 3).
Bound ADP had an effect on cleavage that was less dramatic in
D1161A-IRKD than in WT-IRKD (Fig. 1, lane 6 versus 5, and lane 4 versus
3). The primary sites of cleavage, determined by direct amino acid
sequence analysis of the products, were R1164 and K1165, and minor
cleavage at R1155 was responsible for the doublet appearance of the
25-kDa amino-terminal fragment and 16-kDa carboxy-terminal fragment.
The appearance of the 20-kDa fragment came from direct cleavage of the
activation loop in the 46-kDa IRKD, before cleavage in the carboxy
terminus which occurred at or near R1304. The appearance of this
fragment in both the WT-IRKD control and the D1161A-IRKD mutant
protein, which we had not reported before (18), was due to
the more aggressive proteolysis conditions employed here.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 1.
Limited tryptic cleavage of IRKD in the activation loop.
SDS-PAGE and silver staining give the size distribution of proteins
before and after limited proteolysis. The purified WT-IRKD and
D1161A-IRKD had molecular masses of 46 kDa (lanes 1 and 2, respectively). Tryptic cleavage of these kinases was done for 10 min in
the absence (lanes 3 and 5) or presence (lanes 4 and 6) of 10 mM ADP at
20 mM MgAc2. The IRKD/trypsin ratio was 20:1 (wt/wt), and 2 µg of IRKD was used in every lane. Cleavage of the 46-kDa kinase
domain at or near R1304 in the carboxy terminus gave the 41-kDa tryptic
core. Major cleavage in the activation loop at R1164 and K1165 gave the
25-kDa amino-terminal fragment of 25 kDa, and the 16-kDa
carboxy-terminal fragment from the T core, as described previously
(18). Minor cleavage at R1155 caused the doublet
appearance of these fragments. Under the present conditions, a 20-kDa
fragment came directly from activation loop cleavage of the 46-kDa
kinase domain.
|
|
A second assay for conformational change in the IRKD is iodide
quenching. This serves as a reporter of solvent exposure of the
active-site cleft, which will increase when intrasteric inhibition is
relieved by autophosphorylation (3). As shown previously and reconfirmed here, there was very little iodide quenching in the
basal-state WT-IRKD (Fig. 2A). Here we
observed increased iodide quenching when the WT-IRKD-MgADP binary
complex was formed with saturating ADP (Fig. 2A). In addition,
the Stern-Volmer plot became distinctly curved. The iodide quenching
observed with the D1161A-IRKD alone was similar to the WT-IRKD-MgADP
binary complex. There was very little effect of bound ADP on quenching
measured by steady-state fluorescence, and both plots with the
D1161A-IRKD showed approximately the same curvature as that with the
WT-IRKD-MgADP binary complex. When the data were analyzed using a
modified Stern-Volmer plot (Fig. 2B), approximately 60% of the net
fluorescence was found accessible to quencher in the WT-IRKD-MgADP
binary complex, the D1161A-IRKD alone, and the D1161A-IRKD-MgADP
binary complex (fa) (Table
1). From the slopes and intercepts shown
in Fig. 2B, the Stern-Volmer constant
Ksv was calculated for each kinase (Table 1). On average, the increase was 14-fold higher than the basal
value. The bimolecular collisional rate constant
kq was calculated from the
intensity-weighted mean fluorescence lifetimes (
0) for each kinase determined by
time-resolved fluorescence decay measured in the absence and presence
of MgADP. As shown in Table 1, bound MgADP caused about a 1-ns decrease
in
0 for each kinase. The collisional rate constant
kq for WT-IRKD is similar to that observed
previously (0.4 × 108
M
1 s
1)
(3). The value for kq for
D1161A-IRKD is 13-fold higher than that of WT-IRKD. The value of
kq is the same when comparing the WT-IRKD- and D1161A-IRKD-MgADP binary complexes to each other. Together, the proteolysis and fluorescence studies strongly suggest conformational similarities between the binary complexes of the WT and
mutant kinases.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 2.
Iodide quenching of tryptophan fluorescence.
Steady-state fluorescence was measured with 50 mM TrisAc, pH 7.0, at
constant 0.6 M total potassium salts and 20 mM MgAc2 with
0.6 µM unphosphorylated IRKD in the absence or presence of 10 mM ADP.
(A) Stern-Volmer plot for WT-IRKD ( , ) and D1161A-IRKD ( , )
in the absence ( , ) or presence ( , ) of 10 mM ADP. The
fluorescence intensity was determined with ex = 300 nm, without (F0) or with (F)
potassium iodide, by integration of the emission spectrum from 310 to
420 nm after correction for a blank spectrum at each iodide
concentration (without or with ADP present). (B) The modified
Stern-Volmer plot of the experiments shown in panel A; the same symbols
are used. The fraction of fluorescence that was quenchable under each
condition is obtained by extrapolation to 0 M KI, using equation 2. These solid lines were generated by linear regression.
|
|
To be certain that these effects on conformation were due to the
mutation and not to undetected phosphorylation, we compared the HPLC
elution profiles from endoproteinase Lys-C digests of the two purified
proteins (Fig. 3). In this analysis, the
only significant difference between these proteins was the elution time
of the activation loop peptide, which displayed greater retention in
reverse-phase chromatography in accordance with the nature of the
carboxylic acid side chain to apolar side-chain mutation. The identity
of the peptide in this absorbance peak and the Asp-to-Ala mutation were
confirmed by direct amino acid sequence analysis. Furthermore, these
elution profiles show that neither WT-IRKD nor D1161A-IRKD contained
detectable activation loop phosphotyrosine, shown by the absence of
phosphopeptides in the elution profile, whose known elution positions
are marked in Fig. 3. A conservative estimate of the sensitivity
in this system is 5% conversion of an apopeptide to a phosphopeptide.
Therefore, the properties of D1161-IRKD described so far which report
on the major species in solution are those of the unphosphorylated
protein.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
Peptide mapping of WT-IRKD and D1161A-IKRD. Each IRKD
was digested using endoproteinase Lys-C, and the resulting peptides
were separated by reverse-phase HPLC. The elution profile from a blank
injection (lacking only IRKD) was subtracted. The elution profile for
WT-IRKD (above the zero absorbance line) and the mirror image of the
D1161A-IRKD elution profile (below the zero absorbance line) at 230 nm
are shown. The peptides in every peak of absorbance were identified by
amino acid sequencing. Peptides containing autophosphorylation sites in
the carboxy terminus (CT), activation loop (AL), and juxtamembrane
region (JM) are identified. The D1161A mutation causes the activation
loop peptide (AL*) to elute later than the corresponding peptide from
the WT-IRKD. The elution positions of the activation loop
phosphopeptides are marked with bars; these were determined from
separate experiments with each IRKD.
|
|
Steady-state kinetics of D1161A-IRKD.
Steady-state kinetic
parameters obtained from synthetic peptide phosphorylation are
summarized in Table 2. The magnitude of
Km ATP differs from values reported
earlier by us and others (6, 11), primarily because
Mg2+ is used exclusively rather than
Mn2+ or a
Mn2+-Mg2+ mixture as
the obligatory cation for ATP in the kinase reaction. Mn2+ often produces a lower Km
ATP value for protein tyrosine kinases
(45). We use Mg2+ in this report and
other studies (1, 7, 47) for consistency with the IRKD
catalytic core crystal structures where Mg2+ has
been employed (24, 47) and solution studies of other protein tyrosine kinases (see, for example, reference 43).
Comparing unphosphorylated D1161A-IRKD to unphosphorylated WT-IRKD, the data in Table 2 show that kcat was
about 10-fold higher and Km MgATP was
15-fold lower, with Km IRS939
essentially unchanged. The activation that resulted from
autophosphorylation was characterized for both kinases. Activation of
D1161A-IRKD had almost no effect on kcat,
producing only a 2-fold decrease in Km
MgATP but a 25-fold decrease in Km
IRS939. There are no significant differences in any of
these activated-state kinetic parameters compared to that of activated
WT-IRKD. This indicates that the mutation does not perturb the
enzymatic activity of the kinase in the activated state. The impact of
changing the activation loop conformation on the process of
autophosphorylation is considered next.
Autophosphorylation of D1161A-IRKD and WT-IRKD in vitro.
To
compare the progress of autophosphorylation using kinase domains with a
15-fold difference in Km MgATP we
used 10 mM ATP to saturate both enzymes. Under these conditions WT-IRKD and D1161A-IRKD followed approximately the same time course for autophosphorylation (Fig. 4A). With 0.5 mM MgATP, autophosphorylation of the WT-IRKD was slower, but
autophosphorylation for the D1161A-IRKD was unaffected (Fig. 4B versus
A). Therefore, the gate-open conformation in this mutant IRKD shows a
greater biochemical predisposition for trans
autophosphorylation than WT-IRKD, based on its ability to maintain a
high rate of autophosphorylation at the lower ATP concentration.
Because previous studies showed that WT-IRKD mimics WT-IR in the
absence of insulin (32, 34), it is reasonable to expect
that a full-length IR bearing the D1161A mutation also will be in a
gate-open conformation and display greater autophosphorylation than
WT-IR, at least in the absence of insulin.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 4.
In vitro autophosphorylation of WT-IRKD (WT) and
D1161A-IRKD (DA). The progress of autophosphorylation with 2 µM IRKD and 10 mM (A) or 0.5 mM (B) ATP was monitored by
nondenaturing PAGE and silver staining (7); increased
electrophoretic mobility indicates increased stoichiometries of
autophosphorylation. The zero time results show the unphosphorylated
D1161A-IRKD has lower mobility than the unphosphorylated WT-IRKD
because of the anionic state-to-neutral state mutation. At 60 min, the
activation loop was 80% tris phosphorylated and 20% bis
phosphorylated, and there was extensive autophosphorylation in the
carboxy-terminal and juxtamembrane regions, determined by HPLC peptide
mapping (not shown). The final stoichiometry of autophosphorylation was
5.5 ± 0.6 mol of phosphate per mol of IRKD.
|
|
Autophosphorylation of D1161A-IR and WT-IR in vitro.
WT and
mutant IRs were expressed in C2C12 myoblasts, and WGA-agarose eluates
enriched for each IR were used to determine the progress of
autophosphorylation at different ATP concentrations. The reactions were
done in the absence and presence of insulin, and compared by
densitometric quantitation of antiphosphotyrosine Western blots (Fig.
5). The rate of autophosphorylation in
the absence of insulin was higher for the D1161A-IR than for the WT-IR at all ATP concentrations tested. The difference in rates was most
pronounced at 0.1 mM ATP (Fig. 5A), intermediate at 0.5 mM ATP (Fig.
5B), and slight at 10 mM ATP (Fig. 5C). Autophosphorylation in the
presence of insulin was faster for D1161A-IR at 0.1 mM ATP (Fig. 5A),
but the rates were essentially the same at 0.5 and 10 mM ATP (Fig. 5B
and C, respectively). These results confirm that the activation loop
mutation enhances autophosphorylation of the full-length receptor in
the absence of insulin. ATP dependence for the relative differences in
autophosphorylation in the absence of insulin was qualitatively similar
to the effects observed using the isolated kinase domains, since the
difference was more pronounced at the lower ATP concentrations. The
results also show that insulin stimulation in vitro will normalize the
progress of IR autophosphorylation at 10 and 0.5 mM ATP, which should
bracket the range of intracellular ATP concentrations.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
In vitro autophosphorylation of WT-IR and D1161A-IR.
Time courses of WT-IR ( , ) and D1161A-IR ( , ) were done in
the absence ( , ) or presence ( , ) of insulin. Reactions
were done at 0.1 (A), 0.5 (B), and 10 (C) mM ATP. The
WGA-agarose-enriched fractions from C2C12 cells expressing each IR were
used. Densitometric analysis of Western blots with antiphosphotyrosine
antibodies, developed by enhanced chemiluminescence, were used to
monitor the progress of IR -subunit autophosphorylation in vitro,
with equal amounts of IR loaded in every lane; data are averaged from
triplicate determinations. Data for each ATP concentration are
normalized to the maximum levels of autophosphorylation observed at 10 mM ATP. Further details are given in Materials and Methods.
|
|
Autophosphorylation of D1161A-IR and WT-IR in cells.
The
D1161A mutation, expressed on the full-length IR, was used to test the
importance of a gate-closed versus gate-open conformation in
maintaining the cellular unphosphorylated state of the IR prior to
insulin stimulation. Both the D1161A-IR and WT-IR were expressed transiently in C2C12 cells. The level of endogenous murine IR was
apparently low or not reactive with the polyclonal antibody raised
against human IRKD (Fig. 6A, lane 1). The
expression and processing of transfected human IR precursor to mature
subunits was the same for WT-IR and D1161A-IR (Fig. 6A, lanes 2 and 3), although the rate of expression of D1161A-IR appeared to be slightly lower in this and other transient transfection experiments. Transfected monolayers were stimulated or not stimulated with insulin, and both
cell lysates and anti-IR immunoprecipitates were analyzed by Western
blotting with antiphosphotyrosine antibodies (Fig. 6B).
Insulin-stimulated
-subunit autophosphorylation of the endogenous murine IR was not detected in these blots. There was no constitutive tyrosine phosphorylation of the WT-IR or D1161A-IR
-subunits in
these cells (Fig. 6B, lanes 3 and 9, and lanes 5 and 11, respectively). Insulin-stimulated autophosphorylation in the transfected cells was
readily observed in the lysates (Fig. 6B, lanes 4 and 6), and the
identity of the prominent tyrosine-phosphorylated 95-kDa protein was
confirmed by immunoprecipitation with anti-IRKD antibodies (Fig. 6B,
lanes 10 and 12). Prior to insulin stimulation there was no increased
basal IRS-1 tyrosine phosphorylation in C2C12 cells overexpressing
D1161A-IR or WT-IR (Fig. 6C, lanes 1 to 3). Insulin-stimulated tyrosine
phosphorylation of IRS-1 in mock-transfected C2C12 cells and cells
overexpressing D1161A-IR or WT-IR (Fig. 6C, lanes 4 to 6) indicated
that endogenous murine IR was sufficient to provide a maximum level of
IRS-1 phosphorylation in these transiently transfected cells;
comparable amounts of IRS-1 were present in each immunoprecipitated
sample (Fig. 6D). These experiments demonstrate no unregulated
signaling despite overexpression of D1161A-IR or WT-IR, shown by the
absence of IR autophosphorylation and the absence of elevated IRS-1
phosphorylation in the absence of insulin.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 6.
Tyrosine phosphorylation of WT and D1161A-IR expressed
in C2C12 cells. (A) The Western blot with antikinase domain antibodies
shows the relative abundance of IR -subunit ( ) and the
glycosylated and uncleaved precursor (pre) from total membranes
isolated from mock-transfected (control) cells (lane 1), cells
transfected with WT-IR (lane 2) and cells transfected with D1161A-IR
(lane 3). Equivalent amounts of membrane protein were loaded in lanes 1 to 3. Lane 4 is a 0.2-ng sample of purified WT-IRKD (KD) as a marker
for antibody sensitivity. (B) The Western blot with antiphosphotyrosine
antibodies was made from cell lysates (lanes 1 through 6) and anti-IR
immunoprecipitates from these lysates (lanes 7 to 12). C2C12 cells were
transiently transfected with control vector (M) (lanes 1, 2, 7, and 8),
WT-IR (WT) (lanes 3, 4, 9, and 10), or the D1161A-IR mutant (DA) (lanes
5, 6, 11, and 12). C2C12 monolayers were serum deprived for 3 h
and then untreated (lanes 1, 3, 5, 7, 9, and 11) or stimulated (lanes
2, 4, 6, 8, 10, and 12) for 8 min with 200 nM insulin. The IR
-subunit ( ) and IRS-1 (IRS) are identified. Markers are shown on
the left in kilodaltons. (C) Antiphosphotyrosine Western blot of IRS-1.
IRS-1 was immunoprecipitated with anti-IRS-1 antibodies from control
cells (lanes 1 and 4), cells expressing WT-IR (lanes 2 and 5), or cells
expressing D1161A-IR (lanes 3 and 6) without stimulation (lanes 1 to 3)
or stimulated for 8 min with 200 nM insulin (lanes 4 to 6). (D) Western
blot with anti-IRS-1 antibody of the same immunoprecipitates shown in
panel C; the lane assignments are the same. For these last two panels,
each immunoprecipitate was divided into equal parts prior to
SDS-PAGE.
|
|
It is possible that increased affinity for ATP, associated with the
intracellular domain of the mutant full-length receptor, might change
the sensitivity to insulin. This would not have been detected in the
above experiment, which examined only the endpoints of insulin
responsiveness. Therefore, we measured the dependence of IR
autophosphorylation on insulin concentration for WT-IR and D1161A-IR
expressed transiently in C2C12 myoblasts. The determination of
-subunit tyrosine phosphorylation was done by Western blot analysis
with antiphosphotyrosine antibodies (Fig.
7A). With Western blot exposures giving
approximately equivalent signals at maximum stimulation (100 nM
insulin), quantitative analysis indicated a 2.5-fold shift to a lower
insulin concentration needed to produce half-maximal
autophosphorylation in D1161A-IR than in WT-IR (Fig. 7B). The
50% effective concentration (EC50) was
approximately 1.5 ± 0.4 and 3.7 ± 0.8 nM insulin,
respectively.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 7.
Insulin dose-response for tyrosine phosphorylation of
WT-IR and D1161A-IR expressed transiently in C2C12 cells. (A) The
Western blot with antiphosphotyrosine antibodies, with enhanced
chemiluminescence, was made from cell lysates. Regions of the Western
blot encompassing the -subunit are shown. Receptors were expressed
after transient transfection of C2C12 cells with WT-IR (WT) or the
D1161A-IR mutant (DA). Prior to insulin treatment, monolayers were
serum deprived for 3 h and then stimulated with 0 to 100 nM
insulin for 10 min, at the concentrations shown above the Western blot.
The results are representative of two experiments. (B) Quantitative
analysis of the dose-response results for IR autophosphorylation, as
shown in panel A, for WT-IR ( ) and D1161A-IR ( ). Data are
averaged from duplicate experiments using films where the densities of
-subunit autophosphorylation at 100 nM insulin were approximately
equal, and error bars represent 1 standard deviation from the average.
Each line is the best fit of the data for a single EC50 for
stimulation of each IR: EC50 = 1.5 ± 0.4 nM
insulin for D1161A-IR and EC50 = 3.7 ± 0.8 nM
insulin for WT-IR.
|
|
The level of IR
-subunit autophosphorylation in a cellular context
is determined by the relative rates of autophosphorylation and
phosphotyrosine phosphatase-dependent dephosphorylation. To determine
what impact the D1161A mutation had on these processes, we compared the
time courses of insulin-stimulated autophosphorylation and the
dephosphorylation that occurs following insulin withdrawal (Fig.
8). Both WT-IR and D1161A-IR achieve
steady-state levels of autophosphorylation within 1 min of insulin
addition. These levels persist, with continued stimulation, to at least
50 min. Within 2 min after insulin withdrawal from monolayers (insulin stimulated for 10 min), a decrease in IR
-subunit phosphorylation was observed. The rate of this decline was slower for D1161A-IR than
for WT-IR, requiring 40 min to reach half the maximal steady-state level versus 10 min for the WT-IR.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 8.
Time courses of insulin stimulation and withdrawal. (A)
Western blots with antiphosphotyrosine antibodies were made with
whole-cell lysates of transiently transfected C2C12 myoblasts with
WT-IR (WT) or the D1161A-IR mutant (DA). Regions of the Western blots
encompassing the -subunit are shown. Continuous stimulation with 200 nM insulin was done for the times indicated (x axis,
bottom). Withdrawal of insulin was preceded by a 10-min stimulation
with 200 nM insulin. Incubation in supplemented DMEM without insulin
was done the times indicated (x axis, top). (B)
Quantitative analysis of these time courses presented as the fraction
of maximum autophosphorylation observed. Data presented are means of
two independent experiments: D1161A-IR stimulation ( ); D1161A-IR
withdrawal ( ); WT-IR stimulation ( ); WT-IR withdrawal ( ).
|
|
 |
DISCUSSION |
The functional significance of conformations observed in crystal
structures has often been determined through rationally designed mutations. Here we sought to understand whether the intrasteric inhibitory conformation of the activation loop was necessary to maintain the unphosphorylated basal state of the IR. This may be a
regulatory feature of the IR family not shared with other RTKs. If it
proves to be conserved across species, then there should be an
essential role maintained by evolutionary pressures.
The gate-closed conformation was recognized immediately as incompatible
with trans autophosphorylation of the activation loop (26), an event that is critical for insulin-dependent
signaling (17, 48, 58). The gate-open conformation can be
promoted by ATP, ADP, or other adenine nucleotide derivative binding in vitro (18). Therefore, to test the function of a gate-open
conformation in cellular signaling we needed to relieve intrasteric
inhibition against ATP binding while preserving the potential for
activation loop autophosphorylation. Two earlier observations led to
the specific mutation used here. With full-length IR, Zhang et al. (58) demonstrated elevated autophosphorylation in vitro
without constitutive signaling in cells by mutating the two adjacent
tyrosines in the activation loop (Y1162F-Y1163F). With IRKD, we had
shown this same double mutant (ALY2F) (6) lowered
the Km MnATP for
cis autophosphorylation, which is in the juxtamembrane
region. These effects most likely arose from the same cause, i.e.,
breaking a subset of noncovalent bonds tethering the activation loop in its gate-closed conformation. The interactions of Y1162 and Y1163 that
would contribute to a gate-closed conformation were detected in the
crystal structure(s). Another prominent set of H-bond interactions across the peptide binding site was between D1161 in the activation loop and R1136, K1085, and Q1208 in the catalytic core, where these
interactions also contribute significantly to the P-1 binding site for
a peptide substrate (24, 26). We show that loss of these
interactions by mutagenesis of D1161 had the desired effects: relieving
intrasteric inhibition against ATP, while permitting activation loop
autophosphorylation and kinase activation.
Limited proteolysis showed that the activation loop in D1161A-IRKD
adopted a conformation different from the WT-IRKD in the absence of
adenine nucleotide. The evidence also suggested similar conformations
of the activation loop were present in the D1161A-IRKD with and without
bound adenine nucleotide, in contrast to the conformational changed
induced by MgADP bound to WT-IRKD (Fig. 1 and reference
18). In support of this conclusion, we analyzed the
intrinsic fluorescence of WT-IRKD, which is dominated by emission of
W1175 in the active-site cleft (3). Because the cleft is blocked by the activation loop, this fluorophore is inaccessible to
collisional quenching by iodide. Opening of the cleft due to autophosphorylation results in greater exposure. Here we demonstrate, by the increased iodide quenching, opening of the cleft in the WT-IRKD-MgADP binary complex. This implies greater steric
accessibility and suggests the term gate-open for such conformations of
the activation loop. Therefore, a gate-open conformation for the
D1161A-IRKD, with or without bound adenine nucleotide, was inferred
from the iodide-quenching results. In terms of steric access, the
bimolecular collisional rate constant of 4.3 × 108 M
1
s
1 is roughly 1 order of magnitude less than
the diffusion limit for iodide collisions with a fully exposed indole
ring (38). This indicates fairly extensive exposure of
W1175 in the active site. There is a twofold difference in
kq for the binary complex versus
kq determined after autophosphorylation
(2.0 × 108 M
1
s
1) (3). However, there was also a
twofold difference in kq for the same
gate-closed unphosphorylated WT-IRKD between these data sets (0.22 × 108 M
1
s
1 reported here versus 0.43 × 108 M
1
s
1 reported previously [3]).
Therefore, these values suggest nearly equivalent solute access; taking
ATP as the solute, steric access of the nucleotide substrate may be
nearly equivalent in the unphosphorylated D1161A-IRKD and the
phosphorylated WT-IRKD. However, access of the peptide substrate is
still restricted in some way, based on the difference in
Km peptide between the
unphosphorylated D1161A-IRKD and the phosphorylated WT-IRKD (Table 2):
this kinetic feature of the D1161A-IRKD is more similar to the
basal-state unphosphorylated WT-IRKD. Additionally, the increase in
kcat in the absence of
autophosphorylation was unexpected, and it may suggest that activation
loop phosphorylation has less of an impact on the orientation of
catalytically essential residues than was anticipated from the
structure of this (24, 26) or other (5, 12, 25, 28,
29) protein kinases. For the hypothesis tested in this study,
the increase in turnover number together with the decrease in
Km MgATP shows that intrasteric inhibition was relieved against ATP. Therefore, limited proteolysis, fluorescence, and kinetic studies provide a consistent description of a
gate-open conformation for the D1161A-IRKD, in which peptide interaction is more similar to the basal-state WT-IRKD but ATP interaction and turnover number are like the activated kinase. We
conclude from these solution studies that the activation loop conformation of the D1161A mutant is different from either the basal or
activated states of the WT kinase. The crystal structure of the
D1161A-IRKD core (residues 978 to 1283) was determined while the
manuscript was under revision (47). That structure and
additional solution studies demonstrate a gate-open conformation of the
activation loop and thermodynamic properties of the mutant protein that
are intermediate between the basal and activated states of the WT-IRKD core.
The mutant D1161A-IRKD is enzymatically active, which is expected,
since none of the known catalytically essential residues were mutated.
The new conformation of the activation loop still imposes a barrier to
peptide substrate binding, which may also decrease the efficiency of
intracellular target protein phosphorylation catalyzed by the
unphosphorylated mutant IR. However, this feature did not mitigate
autophosphorylation by D1161A-IRKD or D1161A-IR. These reactions were
rapid at a superphysiological ATP concentration sufficient to saturate
WT-IRKD or WT-IR. At lower ATP concentrations, the decrease in apparent
rate for the WT-IRKD and WT-IR, compared to the still-rapid
autophosphorylation of the mutant, could have resulted from a decreased
fraction in a gate-open conformation at the lower ATP concentration in
the WT kinase, or it may have been due to the difference in
kcat noted above. Which effect
predominates cannot be determined here, because a single mutant will
not distinguish conformational effects on the substrate kinase
domain from conformational and catalytic effects on the enzyme kinase
domain. The essential feature is that a biochemically active kinase is
more capable of rapid autophosphorylation at a subphysiological ATP
concentration than the WT enzyme. The need for intrasteric inhibition
against ATP and a low turnover number to maintain the unphosphorylated state of the IR prior to insulin binding was tested with this mutant.
The D1161A mutation in the full-length IR did not cause unregulated
(constitutive) autophosphorylation in cells in which this mutant IR was
expressed, despite the relief of intrasteric inhibition against ATP
binding and the increased ability to autophosphorylate in the absence
of insulin. In the physiological range of ATP there may be a
heterogeneous population of WT-IR encompassing ATP-bound and -free
forms of the kinase, but the D1161A-IR should be saturated. The absence
of constitutive autophosphorylation in the D1161A-IR demonstrates that
neither intrasteric inhibition against ATP nor low turnover number is
essential for maintaining the basal unphosphorylated state in cells.
The residual high Km peptide in the
D1161A-IR does not affect receptor autophosphorylation, but it may
contribute to the lack of IRS phosphorylation despite the higher
kcat and lower Km
MgATP. However, the absence of constitutive signaling,
indicated by the absence of pTyr-IRS without insulin stimulation (Fig.
6C), is most simply explained by the finding that autophosphorylation
is a necessary prerequisite for biological signaling through the IR
(10, 13) and that the D1161A-IR was not autophosphorylated
prior to addition of insulin.
The shifted insulin dose-response curve for autophosphorylation
observed as a consequence of the mutation suggests that some linkage is
possible between insulin binding to the extracellular domain and ATP
binding to the intracellular domain or that the mutation itself
directly affects recognition and dephosphorylation by a protein
tyrosine phosphatase (PTPase). The recent report of Salmeen et
al. (42) showed that the PTPase PTP1B
which is associated
with regulation of IR phosphorylation and signaling (15)
might employ Asp1161 as an important determinant for
binding the IR activation loop. A potential alteration in binding
affinity or rates of insulin release during receptor internalization,
as well as the relative contribution of Asp1161 to recognition of the
kinase by PTPases, is currently under investigation.
Our finding that intrasteric inhibition and low turnover number are not
essential for suppression of IR autophosphorylation, and thus insulin
signaling, leaves open the biological importance of the gate-closed
conformation. Many protein kinases do not bind ATP because of
intrasteric inhibition (e.g., twitchin kinase [23], calcium calmodulin-dependent protein kinases
[19], or cyclin-dependent protein kinases
[12]). In general, relief from intrasteric inhibition is
achieved by allosteric effectors acting through regulatory proteins or
subunits (31), and nucleotide binding at the active site
is not a typical primary regulator. The basal-state IR appears to be an
exception. Its unique feature is not the fact of intrasteric inhibition
but that the closed-to-open conformational change can be affected by
its substrate at physiological concentrations (18). To the
extent that nucleotide binding is necessary for activation loop
autophosphorylation in the substrate kinase domain, we speculate that
the population of IRs primed by nucleotide binding may vary with
intracellular concentrations of adenine nucleotides or derivatives. This may apply under conditions of metabolic stress, since insulin has
a fundamental role in regulation of energy homeostasis. Furthermore, because AMP does not promote the gate-open conformation
(18) and intracellular AMP changes inversely with respect
to ATP and rises under metabolic stress (4, 21),
coordinated regulation with the 5'-AMP-activated protein kinase is
possible. This may be important because the 5'-AMP-activated kinase is
a primary sensor of energy demand (30) whose target
pathways are counterregulated by insulin signaling. Therefore, a
possible advantage of latency may be variable priming of the IR for
responsiveness to insulin under extreme conditions. Whether such an
effect would be more important in peripheral or neuronal tissues
where
the IR is expressed (2, 16, 52)
will be investigated in
future studies.
In summary, we have shown that intrasteric inhibition against ATP
binding and low catalytic efficiency are not necessary to maintain the
unphosphorylated basal state of the IR. Important for our broader
understanding of the regulation of signal transduction, this finding
suggests that suppression of kinase activity is not inherently
necessary to prevent premature signaling by an RTK.
This work was supported by NIH grant DK59522 (R.A.K.), and
the Coherent laser was obtained through NSF Instrument Development award DBI 9724330 to William R. Laws.
We thank Henry B. Sadowski and his laboratory for guidance on transient
transfections and handling C2C12 cells, and Henry B. Sadowski
and Mitchell Goldfarb for helpful discussions and critical reading of
the manuscript.
| 1.
|
Ablooglu, A. J., and R. A. Kohanski.
2001.
Activation of the insulin receptor's kinase domain changes the rate-determining step of substrate phosphorylation.
Biochemistry
40:504-513[CrossRef][Medline].
|
| 2.
|
Adamo, M.,
M. K. Raizada, and D. LeRoith.
1989.
Insulin and insulin-like growth factor receptors in the nervous system.
Mol. Neurobiol.
3:71-100[Medline].
|
| 3.
|
Bishop, S. M.,
J. B. A. Ross, and R. A. Kohanski.
1999.
Autophosphorylation dependent destabilization of the insulin receptor kinase domain: tryptophan-1175 reports changes in the catalytic cleft.
Biochemistry
38:3079-3089[CrossRef][Medline].
|
| 4.
|
Boiteux, A.,
B. Hess, and E. E. Sel'kov.
1980.
Creative functions of instability and oscillations in metabolic systems.
Curr. Top. Cell. Regul.
17:171-203[Medline].
|
| 5.
|
Canagarajah, B. J.,
A. Khokhlatchev,
M. H. Cobb, and E. J. Goldsmith.
1997.
Activation mechanism of the MAP kinase ERK2 by dual phosphorylation.
Cell
90:859-869[CrossRef][Medline].
|
| 6.
|
Cann, A. D., and R. A. Kohanski.
1997.
Cis-autophosphorylation of juxtamembrane tyrosines in the insulin receptor kinase domain.
Biochemistry
36:7681-7689[CrossRef][Medline].
|
| 7.
|
Cann, A. D.,
S. M. Bishop,
A. J. Ablooglu, and R. A. Kohanski.
1998.
Partial activation of the insulin receptor kinase domain by juxtamembrane autophosphorylation.
Biochemistry
37:11289-11300[CrossRef][Medline].
|
| 8.
|
Cann, A. D.,
I. Wolf, and R. A. Kohanski.
1997.
A tyrosine kinase assay using reverse-phase high-performance liquid chromatography.
Anal. Biochem.
247:327-332[CrossRef][Medline].
|
| 9.
|
Chen, J.,
H. B. Sadowski,
R. A. Kohanski, and L.-H. Wang.
1997.
Stat5 is a physiological substrate of the insulin receptor.
Proc. Natl. Acad. Sci. USA
94:2295-2300[Abstract/Free Full Text].
|
| 10.
|
Chou, C. K.,
T. J. Dull,
D. S. Russell,
R. Gherzi,
D. Lebwohl,
A. Ullrich, and O. M. Rosen.
1987.
Human insulin receptor mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin.
J. Biol. Chem.
268:14553-14556[Free Full Text].
|
| 11.
|
Cobb, M. H.,
B. C. Sang,
R. Gonzalez,
E. Goldsmith, and L. Ellis.
1989.
Autophosphorylation activates the soluble cytoplasmic domain of the insulin receptor in an intermolecular reaction.
J. Biol. Chem.
264:18701-18706[Abstract/Free Full Text].
|
| 12.
|
De Bondt, H. L.,
J. Rosenblatt,
J. Jancarik,
H. D. Jones,
D. O. Morgan, and S. H. Kim.
1993.
Crystal structure of cyclin-dependent kinase 2.
Nature
363:595-602[CrossRef][Medline].
|
| 13.
|
Ebina, Y.,
E. Araki,
M. Taira,
F. Shimada,
M. Mori,
C. S. Craik,
K. Siddle,
S. B. Pierce,
R. A. Roth, and W. J. Rutter.
1987.
Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin- and antibody-stimulated glucose uptake and receptor kinase activity.
Proc. Natl. Acad. Sci. USA
84:704-708[Abstract/Free Full Text].
|
| 14.
|
Ebina, Y.,
L. Ellis,
K. Jarnagin,
M. Edery,
L. Graf,
E. Clauser,
J. H. Ou,
F. Masiarz,
Y. W. Kan,
I. D. Goldfine,
R. A. Roth, and W. J. Rutter.
1985.
The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling.
Cell
40:747-758[CrossRef][Medline].
|
| 15.
|
Elchebly, M.,
P. Payette,
E. Michaliszyn,
W. Cromlish,
S. Collins,
A. L. Loy,
D. Normandin,
A. Cheng,
J. Himms-Hagen,
C.-C. Chan,
C. Ramachandran,
M. J. Gresser,
M. L. Tremblay, and B. P. Kennedy.
1999.
Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene.
Science
283:1544-1548[Abstract/Free Full Text].
|
| 16.
|
Folli, F.,
S. Ghidella,
L. Bonfanti,
C. R. Kahn, and A. Merighi.
1996.
The early intracellular signaling pathway for the insulin/insulin-like growth factor receptor family in the mammalian central nervous system.
Mol. Neurobiol.
13:155-183[Medline].
|
| 17.
|
Flores-Riveros, J. R.,
E. Sibley,
T. Kastelic, and M. D. Lane.
1989.
Substrate phosphorylation catalyzed by the insulin receptor tyrosine kinase. Kinetic correlation to autophosphorylation of specific sites in the beta subunit.
J. Biol. Chem.
264:21557-21572[Abstract/Free Full Text].
|
| 18.
|
Frankel, M.,
S. M. Bishop,
A. J. Ablooglu,
Y.-P. Han, and R. A. Kohanski.
1999.
Conformational changes in the activation loop of the insulin receptor's kinase domain.
Protein Sci.
8:2158-2165[Abstract].
|
| 19.
|
Goldberg, J.,
A. C. Nairn, and J. Kuriyan.
1996.
Structural basis for the autoinhibition of calcium/calmodulin-dependent protein kinase I.
Cell
84:875-887[CrossRef][Medline].
|
| 20.
|
Hasselbacher, C. A.,
E. Waxman,
L. T. Galati,
P. B. Contino,
J. B. A. Ross, and W. R. Laws.
1991.
Investigation of hydrogen bonding and proton transfer of aromatic alcohols in nonaqueous solvents by steady-state and time-resolved fluorescence.
J. Phys. Chem.
95:2995-3005[CrossRef].
|
| 21.
|
Hess, B., and A. Boiteux.
1971.
Oscillatory phenomena in biochemistry.
Annu. Rev. Biochem.
40:237-258[CrossRef][Medline].
|
| 22.
|
Ho, S. N.,
H. D. Hunt,
R. M. Horton,
J. K. Pullen, and L. R. Pease.
1989.
Site-directed mutagenesis by overlap extension using the polymerase chain reaction.
Gene
77:51-59[CrossRef][Medline].
|
| 23.
|
Hu, S. H.,
M. W. Parker,
J. Y. Lei,
M. C. Wilce,
G. M. Benian, and B. E. Kemp.
1994.
Insights into autoregulation from the crystal structure of twitchin kinase.
Nature
369:581-584[CrossRef][Medline].
|
| 24.
|
Hubbard, S. R.
1997.
Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog.
EMBO J.
16:5572-5581[CrossRef][Medline].
|
| 25.
|
Hubbard, S. R.,
M. Mohammadi, and J. Schlessinger.
1998.
Autoregulatory mechanisms in protein-tyrosine kinases.
J. Biol. Chem.
273:11987-11990[Free Full Text].
|
| 26.
|
Hubbard, S. R.,
L. Wei,
L. Ellis, and W. A. Hendrickson.
1994.
Crystal structure of the tyrosine kinase domain of the human insulin receptor.
Nature
372:746-754[CrossRef][Medline].
|
| 27.
|
Issad, T.,
J. M. Tavare, and R. M. Denton.
1991.
Analysis of insulin receptor phosphorylation sites in intact rat liver cells by two-dimensional phosphopeptide mapping. Predominance of the tris-phosphorylated form of the kinase domain after stimulation by insulin.
Biochem. J.
275:15-21.
|
| 28.
|
Johnson, L. N.,
E. D. Lowe,
M. E. Noble, and D. J. Owen.
1998.
The eleventh Datta lecture. The structural basis for substrate recognition and control by protein kinases.
FEBS Lett.
430:1-11[CrossRef][Medline].
|
|